G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Neuropathic Pain and Cardiac Research

Introduction: Redefining GPR30 Agonist Applications Beyond Cell Assays

G-1 (CAS 881639-98-1), a potent and selective agonist for the G protein-coupled estrogen receptor GPR30 (GPER1), has become a cornerstone for probing non-classical estrogen receptor signaling. While existing literature has extensively covered G-1’s utility in cell viability and proliferation assays within oncology and cardiovascular research (see this workflow-focused guide), this article advances the discussion by synthesizing recent breakthroughs in GPR30-mediated neuropathic pain modulation and chronic heart failure models. By merging molecular pharmacology with disease-relevant models, we establish G-1 as not only a tool for in vitro investigations but also a translational agent in preclinical research.

Biochemical and Pharmacological Profile of G-1: A Selective GPR30 Agonist

Structural and Physicochemical Properties

G-1 is a crystalline solid with a molecular formula C21H18BrNO3 and a molecular weight of 412.28 Da. Uniquely DMSO-soluble at ≥41.2 mg/mL, yet insoluble in water and ethanol, G-1’s physicochemical characteristics facilitate its integration into a broad range of experimental protocols. For optimal results, researchers are advised to prepare stock solutions in DMSO at concentrations above 10 mM, employing mild warming and ultrasonic treatment to ensure full dissolution. To maintain bioactivity, solutions should be stored at -20°C and used promptly, as G-1 is susceptible to degradation over time.

Receptor Selectivity and Affinity

Distinguished by its high affinity and selectivity for GPR30/GPER1 (Ki ≈ 11 nM), G-1 exhibits negligible binding to classical estrogen receptors ERα and ERβ even at micromolar concentrations. This selectivity underpins its value as a chemical agonist for GPR30, enabling scientists to dissect estrogen receptor-independent signaling and GPR30-mediated biological effects without confounding activation of nuclear ERs.

Mechanism of Action: GPR30-Driven Intracellular Signaling Pathways

Endoplasmic Reticulum Localization and Non-Genomic Effects

Unlike classical estrogen receptors, GPR30 is an integral membrane protein predominantly located within the endoplasmic reticulum. Upon activation by G-1, GPR30 initiates rapid, non-genomic signaling events. These include:

• Intracellular Calcium Elevation: G-1 induces a robust increase in cytosolic calcium (EC50 = 2 nM), a hallmark of GPR30 activation and a key modulator of downstream cellular responses.
• PI3K Signaling Pathway and PIP3 Nuclear Accumulation: G-1 triggers PI3K-dependent nuclear accumulation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), orchestrating cell survival, migration, and metabolic adaptation via the PI3K/Akt/mTOR signaling axis.

These effects position G-1 as an invaluable probe for delineating GPR30-mediated signaling distinct from classical estrogen pathways.

GPR30 Activation in Cardiovascular Research: Cardiac Fibrosis and Heart Failure Models

In Vivo Efficacy in Heart Failure Animal Models

Chronic administration of G-1 in female Sprague-Dawley rats subjected to bilateral ovariectomy and heart failure induction (120 μg/kg for 14 days) resulted in:

• Cardiac Fibrosis Attenuation: G-1 significantly inhibited fibrotic remodeling, as evidenced by reduced collagen deposition and suppressed profibrotic gene expression.
• Improved Cardiac Function: Restoration of contractile function was observed, partly through normalization of β1-adrenergic receptor expression and upregulation of β2-adrenergic receptors, supporting a cardioprotective phenotype.
• Endocrine Markers: Levels of brain natriuretic peptide (BNP), a clinical surrogate for heart failure severity, were reduced post-treatment.

These findings highlight the translational potential of G-1 as a GPR30 agonist for cardiac function improvement and cardiac fibrosis inhibition, distinguishing it from classical estrogen therapies which often lack receptor specificity and pose off-target risks.

G-1 in Breast Cancer Research: Selective Inhibition of Cell Migration

In vitro, G-1 inhibits migration of breast cancer cell lines SKBr3 and MCF7 with IC50 values of 0.7 nM and 1.6 nM, respectively. Notably, this activity is restricted to cells co-expressing GPR30 and estrogen receptors, underscoring the inhibition of breast cancer cell migration via a GPR30-mediated mechanism. These results extend beyond basic cell viability assays, as previously discussed in prior mechanistic explorations. Here, we focus on G-1's ability to modulate metastatic potential and intracellular signaling, rather than simply its effects on proliferation.

Novel Insights: GPR30 in Neuropathic Pain Modulation

Emergence of GPR30 as a Target in Chronic Pain

Recent advances have uncovered a pivotal role for GPR30 in neuropathic pain, as demonstrated in a comprehensive study by Chen, Wu, Xie et al. (2024). This work identified GPR30 expression in spinal cholecystokinin-positive (CCK+) neurons and S1-SDH post-synaptic neurons, which are critically involved in pain transmission and mechanosensory processing.

Key Findings from Neuropathic Pain Models

• Upregulation in Chronic Injury: GPR30 was significantly upregulated in spinal CCK+ neurons following chronic constriction injury (CCI), a widely used neuropathic pain model.
• Functional Reversal of Allodynia: Inhibition of GPR30 in these neurons reversed CCI-induced mechanical allodynia and thermal hyperalgesia, confirming its role in pain modulation.
• Synaptic Plasticity: GPR30 activation enhanced AMPA-mediated excitatory synaptic transmission in CCI mice, linking estrogenic modulation to central pain sensitization.
• Circuit Integration: Direct projections from the primary sensory cortex to GPR30+ spinal neurons were implicated in the maintenance of neuropathic pain states.

These discoveries extend the functional landscape of G-1 from traditional cardiovascular and cancer biology into neuropathic pain research. Unlike articles focused on cell assay optimization (see detailed workflow analysis), our focus is on G-1’s mechanistic contribution to disease-relevant neural circuits.

For further reading, the foundational study is available as: Chen, Wu, Xie et al. (2024), "GPR30 in spinal cholecystokinin-positive neurons modulates neuropathic pain." eLife 2024;13:RP102874.

Comparative Analysis: G-1 Versus Alternative GPR30 Modulators

While alternative G protein-coupled estrogen receptor agonists and ligands have been reported, most lack the specificity, potency, and pharmacokinetic stability of G-1. Non-selective modulators often activate classical ERα/ERβ, confounding experimental interpretation and increasing off-target effects. G-1’s chemical profile, high selectivity, and established in vivo efficacy make it the preferred GPR30 selective ligand for both mechanistic and translational studies.

In comparison to product-focused articles such as this translational model guide, our analysis uniquely integrates in vivo cardiac and neuropathic pain models, offering a systems-level perspective on G-1's research utility.

Advanced Applications and Protocol Optimization

Optimizing Experimental Use

• Solubility and Handling: Always dissolve G-1 in DMSO, using warming and sonication to achieve concentrations above 10 mM. Avoid aqueous or ethanol-based solutions to maintain compound stability.
• Storage: Prepare aliquots and store at -20°C. Minimize freeze-thaw cycles and use fresh solutions to prevent degradation.
• Shipping: G-1 should be shipped on blue ice to protect its chemical integrity during transit.

Ethical and Safety Considerations

G-1 is intended exclusively for scientific research and is not approved for diagnostic or therapeutic applications in humans or animals. All local regulations and biosafety guidelines must be observed during its handling and experimental use.

Translational Potential: GPR30 Agonists in Disease Modeling and Chemoprevention

The emerging evidence positions G-1 as a versatile cardioprotective agent in research and a valuable tool in chemoprevention studies. Its ability to modulate intracellular calcium signaling, PI3K/Akt/mTOR pathways, and β-adrenergic receptor expression underpins its broad applicability, from cancer metastasis inhibition to cardiac function improvement and neuropathic pain attenuation.

For researchers seeking to leverage G-1 in their studies, APExBIO offers G-1 (CAS 881639-98-1), a selective GPR30 agonist (SKU B5455), ensuring reproducibility and batch-to-batch consistency essential for high-quality research.

Conclusion and Future Outlook

G-1, the prototypical selective GPR30 agonist, has evolved from a cell assay reagent into a multifaceted probe for elucidating estrogen receptor-independent mechanisms in cardiovascular, oncological, and neurobiological contexts. This article offers a distinct perspective by centering on advanced disease models—particularly neuropathic pain and heart failure—that have not been the primary focus of prior workflow or cell assay optimization content. As GPR30’s roles in neural circuitry and cardiac remodeling continue to unfold, G-1 remains an essential tool for translational research and preclinical innovation. For further experimental details and product specifications, researchers are encouraged to consult the APExBIO G-1 product page.